ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Launched by HOSPITAL OF MACERATA · Dec 28, 2023

Keywords

ClinConnect Summary

The ARON-3 Study is an international research project that aims to gather real-world information about how patients with metastatic prostate cancer (PCa) are treated. The study focuses on three specific groups of patients: those receiving hormone therapy combined with targeted treatments (like Apalutamide or Enzalutamide), patients treated with Lutetium-177 PSMA therapy for castration-resistant prostate cancer (CRPC), and those using PARP inhibitors, either alone or with other therapies. By studying these different treatment approaches, the researchers hope to understand their effectiveness and gather valuable data for future patient care.

To be eligible for the study, participants must be over 18 years old and have a confirmed diagnosis of prostate cancer that has spread. For the first group, they need to have received specific combinations of hormone therapy and targeted treatments. For the second group, they must have had Lutetium-177 PSMA therapy, while the third group requires a specific genetic status (HRD positive) and treatment with PARP inhibitors. Participants can expect to contribute to important research that may help improve treatment options for prostate cancer in the future. This study is currently recruiting, and both men and women can participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged \>18y
• • Cytological or Histologically confirmed diagnosis of PC
• • Histologically or radiologically confirmed diagnosis of metastatic disease and
• • For ARON-3S
• • ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)
• • For ARON-3Lu
• • ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC
• • For ARON-3GEN
• • HRD POSITIVE STATUS
• • Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
• Exclusion Criteria:
• • Patients without histologically confirmed diagnosis of PC
• • Patients without histologically or radiologically confirmed metastatic disease and
• • For ARON-3S
• • ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section
• • For ARON-3Lu
• • ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC
• • For ARON-3GEN
• • HRD NEGATIVE STATUS
• • Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study